Literature DB >> 17344212

Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation.

Gui Su1, Stacy A Blaine, Dianhua Qiao, Andreas Friedl.   

Abstract

The cell surface heparan sulfate proteoglycan syndecan-1 is induced in stromal fibroblasts of breast carcinomas and participates in a reciprocal feedback loop, which stimulates carcinoma cell growth in vitro and in vivo. To define the molecular mechanism of carcinoma growth stimulation, a three-dimensional co-culture model was developed that combines T47D breast carcinoma cells with immortalized human mammary fibroblasts in collagen gels. By silencing endogenous syndecan-1 induction with short interfering RNA and expressing mutant murine syndecan-1 constructs, it was determined that carcinoma cell mitogenesis required proteolytic shedding of syndecan-1 from the fibroblast surface. The paracrine growth signal was mediated by the syndecan-1 heparan lfate chains rather than the ectodomain of the core protein and required fibroblast growth factor 2 and stroma-derived factor 1. This paracrine pathway may provide an opportunity for the therapeutic disruption of stromaepithelial signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17344212     DOI: 10.1074/jbc.M611739200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

Review 1.  Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression.

Authors:  Pepper Schedin; Patricia J Keely
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

2.  Mammary fibroblasts regulate morphogenesis of normal and tumorigenic breast epithelial cells by mechanical and paracrine signals.

Authors:  Inke Lühr; Andreas Friedl; Thorsten Overath; Andreas Tholey; Thomas Kunze; Felix Hilpert; Susanne Sebens; Norbert Arnold; Frank Rösel; Hans-Heinrich Oberg; Nicolai Maass; Christoph Mundhenke; Walter Jonat; Maret Bauer
Journal:  Cancer Lett       Date:  2012-07-07       Impact factor: 8.679

Review 3.  The mutual impact of syndecan-1 and its glycosaminoglycan chains--a multivariable puzzle.

Authors:  Anna S Eriksson; Dorothe Spillmann
Journal:  J Histochem Cytochem       Date:  2012-08-16       Impact factor: 2.479

4.  Automation of three-dimensional cell culture in arrayed microfluidic devices.

Authors:  Sara I Montanez-Sauri; Kyung Eun Sung; John P Puccinelli; Carolyn Pehlke; David J Beebe
Journal:  J Lab Autom       Date:  2011-05-16

Review 5.  Soluble syndecans: biomarkers for diseases and therapeutic options.

Authors:  Jessica Bertrand; Miriam Bollmann
Journal:  Br J Pharmacol       Date:  2018-07-23       Impact factor: 8.739

6.  A transmembrane C-terminal fragment of syndecan-1 is generated by the metalloproteinase ADAM17 and promotes lung epithelial tumor cell migration and lung metastasis formation.

Authors:  Tobias Pasqualon; Jessica Pruessmeyer; Sarah Weidenfeld; Aaron Babendreyer; Esther Groth; Julian Schumacher; Nicole Schwarz; Bernd Denecke; Holger Jahr; Pascale Zimmermann; Daniela Dreymueller; Andreas Ludwig
Journal:  Cell Mol Life Sci       Date:  2015-04-26       Impact factor: 9.261

Review 7.  Mechanisms of heparanase inhibitors in cancer therapy.

Authors:  Benjamin Heyman; Yiping Yang
Journal:  Exp Hematol       Date:  2016-08-26       Impact factor: 3.084

8.  Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate.

Authors:  Koji M Nishiguchi; Keiko Kataoka; Shu Kachi; Keiichi Komeima; Hiroko Terasaki
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

Review 9.  Proteoglycans: master modulators of paracrine fibroblast-carcinoma cell interactions.

Authors:  Andreas Friedl
Journal:  Semin Cell Dev Biol       Date:  2009-11-28       Impact factor: 7.727

10.  Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins.

Authors:  Remedios Castelló-Cros; David R Khan; Jeffrey Simons; Matthildi Valianou; Edna Cukierman
Journal:  BMC Cancer       Date:  2009-03-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.